Introduction
============

One in four women is diagnosed with breast cancer, which is the second leading cause of cancer-related death in women in the United States. Current treatment options include surgery, radiation and systemic therapy (e.g. hormonal therapy, chemotherapy and biological therapy). Major problems with chemotherapy are toxic side effects and emergence of drug resistance. The development of rational therapeutic approaches for breast cancer requires an understanding of the cellular signaling pathways leading to breast cancer. Since estrogen promotes growth of breast cancer and 70% of breast cancer patients are estrogen receptor (ER)-positive, antiestrogens (e.g. tamoxifen) are frequently used to treat patients with breast cancer. Fulvestrant, a novel ER antagonist that degrades ER, is more effective than tamoxifen ([@b37-bcbcr-2008-011]). Aromatase inhibitors (e.g. letrozole, anastrozole and exemestane), which inhibit estrogen synthesis, are now in use to treat postmenopausal women with breast cancer. The use of antiestrogens and aromatase inhibitors is, however, recommended for hormone receptor-positive breast tumors. In addition, inherent and acquired resistance to endocrine therapy is a significant problem ([@b22-bcbcr-2008-011]).

The human epidermal growth factor receptor (EGFR) or HER family of proteins comprised of EGFR (HER1), HER2, HER3 and HER4 are type 1 tyrosine kinase growth factor receptors ([@b4-bcbcr-2008-011]; [@b21-bcbcr-2008-011]). *HER2* gene is amplified or overexpressed in up to 25% of patients with breast cancer ([@b42-bcbcr-2008-011]). It can contribute to both development of breast cancer and its progression to aggressive forms. Herceptin (trastuzumab), a humanized monoclonal antibody against HER2/neu, was the first HER-2-targeted biologic agent approved for the therapy of breast cancer ([Fig. 1](#f1-bcbcr-2008-011){ref-type="fig"}). Although trastuzumab improved the survival of patients with HER2-positive metastatic breast cancers, especially when combined with chemotherapy, the development of resistance to trastuzumab and its high cost restrict its therapeutic use. Several small molecule inhibitors that target EGFR tyrosine kinase activity, (e.g. erlotinib, gefitinib, lapatinib and canertinib), farnesyl transferase inhibitors that target Ras, and rapamycin and its analogues that inhibit mammalian target of rapamycin (mTOR) have been developed ([Fig. 1](#f1-bcbcr-2008-011){ref-type="fig"}). These compounds show limited success as a single agent but they are more effective when combined with trastuzumab, antiestrogens or aromatase inhibitors ([@b19-bcbcr-2008-011]; [@b20-bcbcr-2008-011]).

The development of successful therapeutic agents requires not only identification of appropriate molecular targets but also elucidation of the signaling pathways that may contribute to resistance to these agents. The Akt/protein kinase B (PKB) serine/threonine kinase regulates a myriad of cellular processes, including metabolism, cell proliferation, cell survival and cell growth ([@b52-bcbcr-2008-011]). It mediates its multiple functions by phosphorylating a large number of substrates, including glycogen synthase kinase-3, cyclin D1, cyclin-dependent kinase inhibitors (p27 and p21), caspase-9, Bad, MDM2 and forkhead transcription factors ([@b55-bcbcr-2008-011]; [@b29-bcbcr-2008-011]; [@b52-bcbcr-2008-011]). Activation of Akt has been associated with up to 40% of breast cancers ([@b29-bcbcr-2008-011]). The increase in phospho-Akt level in breast tumor samples correlates with poor prognosis ([@b44-bcbcr-2008-011]; [@b49-bcbcr-2008-011]; [@b58-bcbcr-2008-011]) and predicts a worse outcome among endocrine-treated patients ([@b35-bcbcr-2008-011]). Akt has been associated with tumor progression, invasion, metastasis, and resistance to hormonal and chemotherapy ([@b12-bcbcr-2008-011]; [@b15-bcbcr-2008-011]; [@b29-bcbcr-2008-011]; [@b36-bcbcr-2008-011]; [@b39-bcbcr-2008-011]; [@b57-bcbcr-2008-011]). Thus, Akt is an important therapeutic target for the treatment of breast cancer. This commentary discusses how deregulation in various signaling pathways contributes to breast cancer via activation of the Akt signaling pathway.

Activation of Akt
=================

Although many breast tumors exhibit an increase in constitutively-active Akt, mutations in Akt are rare, suggesting that the elevated Akt activity results from an alteration of regulators of Akt rather than any mutation ([@b47-bcbcr-2008-011]). Akt is activated by a variety of growth factors, including insulin, insulin-like growth factor-1 and epidermal growth factor ([@b39-bcbcr-2008-011]). It acts downstream of phosphoinositide-3 kinase (PI3K) and mediates the survival effects of different growth factors, cytokines and oncogenes ([@b24-bcbcr-2008-011]). Activation of PI3K generates 3-phosphoinositides that bind to the pleckstrin homology (PH) domain of Akt inducing its membrane translocation and conformational change required for its phosphorylation and activation ([@b17-bcbcr-2008-011]). Phosphorylation appears to be critical for its kinase activity ([@b9-bcbcr-2008-011]; [@b17-bcbcr-2008-011]). Akt is phosphorylated at Thr308 in the activation loop by phosphoinositide-dependent protein kinase 1 (PDK1) ([@b3-bcbcr-2008-011], [@b54-bcbcr-2008-011]). Phosphorylation of Akt at the Ser473 site in the carboxy terminal domain is necessary for its full activation. Several kinases, including PDK1, integrin-linked kinase (ILK) ([@b14-bcbcr-2008-011]; [@b50-bcbcr-2008-011]), rictor-mTOR complex ([@b40-bcbcr-2008-011]), mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP kinase-2) ([@b2-bcbcr-2008-011]; [@b38-bcbcr-2008-011]) and DNA-dependent protein kinase (DNA-PK) ([@b16-bcbcr-2008-011]) have been implicated in phosphorylating the Ser473 site in Akt.

The Involvement of Akt Isoforms in Breast Cancer
================================================

Three isoforms of Akt have been identified: Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ ([@b30-bcbcr-2008-011]). Akt1 is the most abundant isoform. All three Akt isoforms have been associated with breast cancer ([@b5-bcbcr-2008-011]; [@b6-bcbcr-2008-011]; [@b33-bcbcr-2008-011]; [@b35-bcbcr-2008-011]; [@b44-bcbcr-2008-011]; [@b46-bcbcr-2008-011]; [@b47-bcbcr-2008-011]; [@b15-bcbcr-2008-011]; [@b28-bcbcr-2008-011]). Akt1 is overexpressed in breast cancer cells and has been shown to be important in estrogen-stimulated growth ([@b1-bcbcr-2008-011]; [@b44-bcbcr-2008-011]). It has been reported that Akt2 is amplified in 3% of breast cancers ([@b6-bcbcr-2008-011]) and is frequently activated in primary human breast carcinoma ([@b46-bcbcr-2008-011]). Akt1 and Akt2 have opposite role in invasion and metastasis. While Akt1 inhibits invasion, metastasis and epithelial to mesenchy-mal transition (EMT), Akt2 facilitates cell migration and EMT ([@b27-bcbcr-2008-011]; [@b48-bcbcr-2008-011]). A recent report suggests that Akt2 contributes to breast cancer metastasis via protein kinase C (PKC)-ζ ([@b53-bcbcr-2008-011]). Upregulation of Akt3 may contribute to the more aggressive clinical phenotype of the ER-negative breast cancers ([@b33-bcbcr-2008-011]) although one report showed Akt3 mRNA expression is not restricted to tumorigenic cell lines or to ER-negative breast cancer cells ([@b59-bcbcr-2008-011]). However, transfection of constitutively active Akt-3 in MCF-7 cells reversed estrogen and tamoxifen response of MCF-7 cells ([@b15-bcbcr-2008-011]). Thus, an understanding of the distinct role of Akt isoforms is essential to exploit the Akt signaling pathway for breast cancer therapy.

Akt Takes Center Stage
======================

Several signaling pathways that are deregulated in breast cancer act via the Akt signaling pathway. Akt is often activated in breast tumors overexpressing HER2 ([@b49-bcbcr-2008-011]). It has been reported that HER2 mediates its oncogenic signaling via the PI3K/Akt signaling pathway ([@b26-bcbcr-2008-011]). Although HER2 does not directly bind to and activate PI3K/Akt, it activates Akt through tyrosine phosphorylation of HER3 ([@b43-bcbcr-2008-011]). HER2 forms heterodimers with HER3 and transphosphorylation of HER3 by HER2 allows HER3 to interact with the p85 regulatory subunit of PI3K ([Fig. 1](#f1-bcbcr-2008-011){ref-type="fig"}), thereby causing activation of PI3K/Akt ([@b43-bcbcr-2008-011]). It has been shown that the p85 regulatory subunit of PI3K can also interact with ERα causing activation of Akt ([@b41-bcbcr-2008-011]). Furthermore, PI3K can cause phosphorylation and activation of ER. Thus, a combination of PI3K/Akt inhibitors with trastuzumab, tyrosine kinase inhibitors and antiestrogens may be more effective in treating breast cancer compared to a single agent.

Since Akt activity is regulated by phosphorylation at the Ser473 site, a deregulation in kinases and phosphatases that regulate phosphorylation at this site can result in activation of Akt. Integrin-linked kinase (ILK) has been shown to phosphorylate Akt at the S473 site although it is not clear if ILK directly phosphorylates Akt or if it acts as a scaffolding protein allowing another kinase to phosphorylate Akt ([@b25-bcbcr-2008-011]). Recently, it has been reported that a rictor/ILK complex regulates phosphorylation of Akt at Ser473 ([@b31-bcbcr-2008-011]). ILK has been associated with breast cancer progression and metastasis through Akt activation ([@b25-bcbcr-2008-011]).

The tumor suppressor protein phosphatase and tensin homolog deleted on chromosome 10 (PTEN) that dephosphorylates the 3 position of phosphoinositides and thereby inactivates Akt is also deregulated in breast carcinoma ([@b8-bcbcr-2008-011]). Although mutations in PTEN have been detected in a small percentage of breast cancers, loss of heterozygosity (LOH) at the PTEN locus is a more common occurrence in breast cancer ([@b23-bcbcr-2008-011]). The reduced expression of PTEN protein was found in 30% of breast cancers and correlated with lymph node metastases and a worse prognosis ([@b51-bcbcr-2008-011]). The PH domain/leucin-rich repeat protein phosphatase (PHLPP) that directly dephosphorylates Ser473 in Akt and thereby inactivates it has recently been identified ([@b18-bcbcr-2008-011]). A decrease in the expression of PHLPP was associated with progression to metastasis in a series of human epithelial cells obtained by successive biopsies from one breast cancer patient ([@b36-bcbcr-2008-011]).

Akt can act both upstream and downstream of mammalian target of rapamycin (mTOR) which regulates protein translation and cell cycle progression via its downstream effectors p70 S6 kinase (p70S6K) and 4E-binding protein-1 ([Fig. 1](#f1-bcbcr-2008-011){ref-type="fig"}). mTOR can form a complex with either raptor or rictor to form mTORC1 or mTORC2, respectively ([@b40-bcbcr-2008-011]). mTORC1, but not mTORC2, is rapamycin sensitive. Akt can activate mTOR by phosphorylating and inactivating the tumor suppressor protein tubersclerosis complex 2 (TSC2), which negatively regulates mTOR activity. Furthermore, persistent activation of p70S6K can lead to feedback inhibition of the PI3K/Akt pathway (O'Reilly et al. 2006). mTOR is critical for the proliferative responses mediated by growth factor receptors ([@b32-bcbcr-2008-011]) and is required for estrogen-induced breast tumor cell proliferation ([@b7-bcbcr-2008-011]). Constitutive signaling through this pathway is a cause of treatment failure in breast cancer patients ([@b11-bcbcr-2008-011]). Rapamycin and its analogues, such as temsirolimus (CCI-779) and everolimus (RAD-001) are in clinical trials ([Fig. 1](#f1-bcbcr-2008-011){ref-type="fig"}). Breast cancer cells with activated Akt are exquisitely sensitive to mTOR antagonists ([@b56-bcbcr-2008-011]). Activation of Akt/mTOR pathway can cause resistance to tamoxifen ([@b10-bcbcr-2008-011]). Combination of mTOR antagonists with antiestrogens and aromatase inhibitors has been effective in treating hormone-sensitive breast cancers ([@b13-bcbcr-2008-011]). A recent study showed that mutation perturbing the lipid and protein phosphatase activities of PTEN caused activation of Akt/mTOR/p70S6K signaling and chemoresistance, whereas rapamycin synergized with doxorubicin to inhibit growth of breast cancer cells ([@b45-bcbcr-2008-011]).

Conclusion
==========

The signaling pathways that are altered in breast cancer or in response to therapy can greatly influence clinical outcome. The development of molecular-targeted therapies presents promises as well as challenges. The PI3K/Akt signaling pathway has received considerable attention because of its critical role in the development and progression of breast cancer. In addition, the status of Akt can influence both inherent and acquired resistance to systemic therapy. In targeting the Akt pathway, one must consider that different Akt isoforms may have redundant, distinct or opposite functions. In addition, the status of different signaling pathways that feed into the Akt signaling pathway may have a significant impact on patient response to therapy. Thus, while combining inhibitors of the PI3K/Akt pathway in conjunction with currently available therapeutic agents may greatly improve their efficacy, finding the right combination is the challenge.
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